Stock Watch: Big Pharma Earnings Season Gets Messy
Recovery Dynamics Vary Across Therapeutic Areas And Pandemic Products
A post-pandemic rebound in oncology sales contrasts with the lagging revenues of drugs administered by primary care and office-based specialists. Declining COVID-19 vaccine, diagnostic and treatment revenues could add further volatility.
You may also be interested in...
Some commercial-stage biotechnology companies blame the pandemic for their declining sales and continued losses. While an acquisition by a bigger company might once have been an aspiration, further fundraisings seem to be the more likely outcome.
The second-order pandemic effects on labor and logistics that have plagued other sectors appeared across J&J’s earnings announcement. With the biggest impact at its consumer business, why then has demand for J&J’s COVID-19 vaccine plummeted?
The evolution of new drugs to treat diabetes has enabled some diabetes franchises to shrug off biosimilar competition to insulins. But is some of the growth of therapies for diabetes and obesity a result of the pandemic?